Revive Therapeutics Announces Final Stages In Bucillamine Phase 3 Clinical Trial For COVID-19
Revive Therapeutics (CSE: RVV) provided on Tuesday updates regarding the phase 3 clinical trial for oral drug bucillamine as a treatment
Read more
Revive Therapeutics
Revive Therapeutics Adds Turkish Subjects To Bucillamine Phase 3 Clinical Trial For COVID-19
Revive Therapeutics (CSE: RVV)Â announced on Wednesday that it has expanded its phase 3 clinical trial for oral drug bucillamine as
Read more
Revive Therapeutics Includes Treating Omicron Variant In Bucillamine Research
Revive Therapeutics (CSE: RVV) announced today that it is expanding its research on oral drug Bucillamine. The firm decided to include
Read more
Revive Therapeutics Announces Research Collaboration Agreement For Psilocybin Microneedle Patch
Revive Therapeutics (CSE: RVV) announced today that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (CSE: PHRM).
Read more
Revive Therapeutics Enters Exclusive License For Ganoderma Lucidum Intellectual Property
Revive Therapeutics (CSE: RVV) last night announced that it has has entered into an exclusive licensing agreement. The licensing agreement
Read more
Revive Therapeutics Provides Update On Current Psilocybin Programs
Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its psychedelic assets. The update primarily
Read more
Revive Therapeutics Begins Laying Groundwork For Commercialization Of Bucillamine
Revive Therapeutics (CSE: RVV) this afternoon reported that it is in the process of pursuing a commercialization plan for the
Read more
Revive Therapeutics Partners With University of Health Sciences Antigua To Further Psychedelics Research
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to further advance its psychedelic-assisted therapies.
Read more
Revive Therapeutics Looks To Bring Bucillamine To India
Revive Therapeutics (CSE: RVV) is looking to India. The company this morning indicated that it has entered into a memorandum
Read more
Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19
Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered into a sponsored research agreement
Read more